NAMS250516P17500
- 2.20
- 0.000.00%
NewAmsterdam Pharma Newsroom
NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress
NewAmsterdam Pharma Company N.V. (NAMS): Among Billionaire Andreas Halvorsen's Stock Picks With Huge Upside Potential
12 Health Care Stocks Moving In Tuesday's After-Market Session
Press Release: NewAmsterdam Pharma Appoints Adele Gulfo to Its Board of Directors
Express News | NewAmsterdam Pharma Appoints Adele Gulfo to Its Board of Directors
Jefferies Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $45
Express News | Form 144 | NewAmsterdam Pharma(NAMS.US) Insider Proposes to Sell 21.67 Million in Common Stocks
TD Cowen Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating
NewAmsterdam Pharma Company (NAMS) Receives a Buy From TD Cowen
Needham Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $42
The Analyst Verdict: NewAmsterdam Pharma Co In The Eyes Of 6 Experts
NewAmsterdam Pharma Price Target Maintained With a $42.00/Share by Needham
NewAmsterdam Pharma Co Analyst Ratings
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
William Blair Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating
William Blair Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)
NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference
Piper Sandler Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $37
NewAmsterdam Pharma Company (NAMS) Gets a Buy From Piper Sandler